| P50 | author | Rachel L. Batterham | Q57033016 |
| P2093 | author name string | William R Scott | |
| P2860 | cites work | Medical Consequences of Obesity | Q22241663 |
| | Body-Mass Index and Mortality among 1.46 Million White Adults | Q22250878 |
| | Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects | Q22250885 |
| | The genetic contribution to non-syndromic human obesity | Q22251027 |
| | Increases in morbid obesity in the USA: 2000-2005 | Q22251191 |
| | Endoplasmic reticulum stress and the inflammatory basis of metabolic disease | Q24633352 |
| | An obesity-associated gut microbiome with increased capacity for energy harvest | Q27860515 |
| | Inhibition of food intake in obese subjects by peptide YY3-36 | Q28204942 |
| | Vagotomy dissociates short- and long-term controls of circulating ghrelin | Q28206897 |
| | Central obesity and increased risk of dementia more than three decades later | Q28274012 |
| | Systematic review: an evaluation of major commercial weight loss programs in the United States | Q28300926 |
| | Prevalence of overweight and obesity in the United States, 1999-2004 | Q28305811 |
| | Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery | Q29614192 |
| | Dynamics of fat cell turnover in humans | Q29615688 |
| | Biology of incretins: GLP-1 and GIP | Q29617302 |
| | Central nervous system control of food intake and body weight | Q29619020 |
| | A role for ghrelin in the central regulation of feeding | Q29620403 |
| | Obesity and the human microbiome | Q30052740 |
| | Role of neuropeptides in appetite regulation and obesity--a review. | Q30356494 |
| | Drug treatments for obesity: orlistat, sibutramine, and rimonabant. | Q30359088 |
| | Peptide YY: food for thought. | Q30375395 |
| | Gut hormones: implications for the treatment of obesity. | Q30378465 |
| | Comparison of competitive radioimmunoassays and two-site sandwich assays for the measurement and interpretation of plasma ghrelin levels | Q30432520 |
| | Bariatric surgery: a systematic review and meta-analysis | Q30769299 |
| | The environment within: how gut microbiota may influence metabolism and body composition | Q33696549 |
| | Effect of gastric bypass surgery on the incretins | Q33743998 |
| | Effect of weight loss by diet or gastric bypass surgery on peptide YY3-36 levels | Q33752066 |
| | Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence? | Q33789529 |
| | Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding | Q33879265 |
| | The medical risks of obesity | Q33888248 |
| | Sleeve gastrectomy induces loss of weight and fat mass in obese rats, but does not affect leptin sensitivity | Q33905715 |
| | Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery | Q33959262 |
| | Metabolic/bariatric surgery Worldwide 2008. | Q34020011 |
| | Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes | Q34032014 |
| | Decreased dopamine type 2 receptor availability after bariatric surgery: preliminary findings | Q34079702 |
| | A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans | Q34085069 |
| | Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin | Q34094232 |
| | Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. | Q34095151 |
| | Minireview: Inflammation and obesity pathogenesis: the hypothalamus heats up. | Q34132288 |
| | Years of life lost due to obesity | Q34169086 |
| | Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis | Q37409707 |
| | The mechanisms of weight loss after bariatric surgery. | Q37442590 |
| | Gut peptides in the control of food intake | Q37442631 |
| | Obesity, inflammation, and insulin resistance--a mini-review | Q37443544 |
| | Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery | Q37446475 |
| | Targeting the CNS to treat type 2 diabetes | Q37464738 |
| | Intestinal microflora and metabolic diseases. | Q37472427 |
| | Obesity, gut hormones, and bariatric surgery. | Q37511828 |
| | The role of gut hormones in the regulation of body weight and energy homeostasis | Q37535112 |
| | Laparoscopic sleeve gastrectomy: a retrospective review of 1- and 2-year results | Q37582309 |
| | Human genetics illuminates the paths to metabolic disease | Q37634967 |
| | Mechanisms facilitating weight loss and resolution of type 2 diabetes following bariatric surgery. | Q37687612 |
| | The effect of bariatric surgery on gut hormones that alter appetite | Q37691662 |
| | Comparison of comorbidity resolution and improvement between laparoscopic sleeve gastrectomy and laparoscopic adjustable gastric banding. | Q37719313 |
| | Morbid obesity and sleeve gastrectomy: how does it work? | Q37728974 |
| | Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up | Q37761428 |
| | Bowels control brain: gut hormones and obesity | Q37768338 |
| | Metabolic syndrome, hormones, and maintenance of T cells during aging | Q37768982 |
| | Long-term results of laparoscopic sleeve gastrectomy for obesity | Q37771841 |
| | Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice | Q38313572 |
| | Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. | Q34325049 |
| | Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity | Q34330489 |
| | Anatomy and regulation of the central melanocortin system | Q34414149 |
| | Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin | Q34513044 |
| | Body-mass index and mortality in Korean men and women. | Q34559686 |
| | Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial | Q34566570 |
| | Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. | Q34570264 |
| | Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and peptide YY. | Q34615425 |
| | Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production | Q34768998 |
| | Will all Americans become overweight or obese? estimating the progression and cost of the US obesity epidemic | Q34811626 |
| | Bariatric surgery and long-term control of morbid obesity | Q35020501 |
| | Ghrelin effects on neuropeptides in the rat hypothalamus depend on fatty acid metabolism actions on BSX but not on gender | Q35592126 |
| | Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution | Q35794463 |
| | The gut and energy balance: visceral allies in the obesity wars | Q36080128 |
| | Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding | Q36259482 |
| | Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism | Q36381636 |
| | Biological, physiological, and pharmacological aspects of ghrelin | Q36447933 |
| | Ileal transposition provides insight into the effectiveness of gastric bypass surgery | Q36510310 |
| | Abdominal obesity and metabolic syndrome | Q36682671 |
| | The role of peptide YY in regulating glucose homeostasis | Q36702234 |
| | Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes | Q36755303 |
| | The lipid messenger OEA links dietary fat intake to satiety. | Q36948170 |
| | Efficacy of surgery in the management of obesity-related type 2 diabetes mellitus | Q36968398 |
| | Quality of life and alteration in comorbidity following laparoscopic adjustable gastric banding | Q37008737 |
| | Vagal sparing surgical technique but not stoma size affects body weight loss in rodent model of gastric bypass | Q37025874 |
| | Adipokines: the missing link between insulin resistance and obesity. | Q37038003 |
| | The effect of laparoscopic gastric banding surgery on plasma levels of appetite-control, insulinotropic, and digestive hormones | Q37095586 |
| | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 |
| | Analysis of the results of sleeve gastrectomy for morbid obesity and the role of ghrelin | Q37179040 |
| | Central and peripheral regulation of food intake and physical activity: pathways and genes | Q37204432 |
| | Global burden of obesity in 2005 and projections to 2030. | Q37209527 |
| | Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass | Q37261091 |
| | Relation of obesity to consummatory and anticipatory food reward | Q37325056 |
| | Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes | Q37345249 |
| | Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans | Q42169738 |
| | Restoration of Euglycemia and Normal Acute Insulin Response to Glucose in Obese Subjects With Type 2 Diabetes Following Bariatric Surgery | Q42440397 |
| | Changes in glucagon-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects | Q42476857 |
| | Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity | Q42634370 |
| | Roux-en-Y gastric bypass enhances energy expenditure and extends lifespan in diet-induced obese rats | Q42867826 |
| | Basal plasma levels of insulin, leptin, ghrelin, and amylin do not signal adiposity in rats recovering from forced overweight | Q42953382 |
| | Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents. | Q43040905 |
| | The influence of nutrients, biliary-pancreatic secretions, and systemic trophic hormones on intestinal adaptation in a Roux-en-Y bypass model | Q43075711 |
| | Gut microbiome-derived metabolites characterize a peculiar obese urinary metabotype. | Q43138002 |
| | Early postoperative insulin-resistance changes after sleeve gastrectomy | Q43241597 |
| | Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes | Q43252994 |
| | Comparison of the effects of Roux-en-Y gastric bypass and ileal transposition surgeries on food intake, body weight, and circulating peptide YY concentrations in rats. | Q43664359 |
| | The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats | Q44165158 |
| | Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects | Q44392867 |
| | Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery. | Q44548921 |
| | Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects. | Q44582488 |
| | Induction of control genes in intestinal gluconeogenesis is sequential during fasting and maximal in diabetes. | Q44618181 |
| | Midlife body mass index and hospitalization and mortality in older age. | Q44676822 |
| | Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease | Q44699316 |
| | Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls | Q44835010 |
| | Changes in serum ghrelin concentration following biliopancreatic diversion for obesity. | Q44848294 |
| | The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus | Q44928631 |
| | Plasma ghrelin in obesity before and after weight loss after laparoscopical adjustable gastric banding | Q44968774 |
| | The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism | Q44992657 |
| | The cholinergic system controls ghrelin release and ghrelin-induced growth hormone release in humans | Q45050687 |
| | Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin | Q45105936 |
| | Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study | Q45178354 |
| | Diabetes, obesity, and the brain | Q45232063 |
| | Laparoscopic adjustable silicone gastric banding vs laparoscopic vertical banded gastroplasty in morbidly obese patients: long-term results of a prospective randomized controlled clinical trial | Q45752787 |
| | Gastric emptying is not affected by sleeve gastrectomy--scintigraphic evaluation of gastric emptying after sleeve gastrectomy without removal of the gastric antrum | Q45811670 |
| | Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. | Q45917277 |
| | Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. | Q45986635 |
| | Effects of ileal transposition on food intake, dietary preference, and weight gain in Zucker obese rats | Q46130835 |
| | Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20-34. | Q46335423 |
| | Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice | Q46398531 |
| | Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study | Q46536937 |
| | Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects | Q46561401 |
| | Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial | Q46620662 |
| | Effects of load, and duration, of duodenal lipid on antropyloroduodenal motility, plasma CCK and PYY, and energy intake in healthy men. | Q46740032 |
| | Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release | Q46779245 |
| | Portal sensing of intestinal gluconeogenesis is a mechanistic link in the diminution of food intake induced by diet protein | Q46791851 |
| | Circulating peptide YY, weight loss, and glucose homeostasis after gastric bypass surgery in morbidly obese subjects | Q46793748 |
| | Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal | Q46982079 |
| | Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass | Q47189295 |
| | Weight loss increases circulating levels of ghrelin in human obesity | Q47191637 |
| | Persistent correlation of ghrelin plasma levels with body mass index both in stable weight conditions and during gastric-bypass-induced weight loss | Q47209015 |
| | Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. | Q47239778 |
| | Laparoscopic sleeve gastrectomy--influence of sleeve size and resected gastric volume | Q47255556 |
| | The serial changes of ghrelin and leptin levels and their relations to weight loss after laparoscopic minigastric bypass surgery | Q47256748 |
| | Suboptimal weight loss after gastric bypass surgery: correlation of demographics, comorbidities, and insurance status with outcomes | Q47257524 |
| | Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass | Q47263805 |
| | Characterization of weight loss and weight regain mechanisms after Roux-en-Y gastric bypass in rats | Q47280174 |
| | Serum ghrelin, leptin and adiponectin levels before and after weight loss: comparison of three methods of treatment--a prospective study | Q47312330 |
| | Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people | Q47314674 |
| | Is ghrelin the culprit for weight loss after gastric bypass surgery? A negative answer | Q47330097 |
| | The effect of biliopancreatic diversion with pylorus-preserving sleeve gastrectomy and duodenal switch on fasting serum ghrelin, leptin and adiponectin levels: is there a hormonal contribution to the weight-reducing effect of this procedure? | Q47337924 |
| | Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters | Q47356520 |
| | Peptide YY is a regulator of energy homeostasis in obese children before and after weight loss | Q47366382 |
| | Thirteen years of follow-up in patients with adjustable silicone gastric banding for obesity: weight loss and constant rate of late specific complications | Q47397858 |
| | Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia | Q47401795 |
| | Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats | Q47405665 |
| | Impact of laparoscopic adjustable gastric banding on plasma ghrelin, eating behaviour and body weight | Q47411049 |
| | Medical and surgical treatments for obesity have opposite effects on peptide YY and appetite: a prospective study controlled for weight loss | Q47448938 |
| | Two-year results on morbidity, weight loss and quality of life of sleeve gastrectomy as first procedure, sleeve gastrectomy after failure of gastric banding and gastric banding | Q47586570 |
| | Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. | Q47790721 |
| | Ghrelin: a gut-brain hormone: effect of gastric bypass surgery | Q48367505 |
| | Comparison between the results of laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass in the Indian population: a retrospective 1 year study | Q48386458 |
| | Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. | Q48457433 |
| | Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function. | Q51168864 |
| | Plasma ghrelin modulation in gastric band operation and sleeve gastrectomy. | Q51439550 |
| | The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. | Q51468040 |
| | GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. | Q51481151 |
| | Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. | Q51488073 |
| | Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. | Q51495618 |
| | Peptide YY levels are elevated after gastric bypass surgery. | Q51500912 |
| | Fasting plasma ghrelin levels increase progressively after biliopancreatic diversion: one-year follow-up. | Q51519450 |
| | Ghrelin, leptin and insulin levels after restrictive surgery: a 2-year follow-up study. | Q51528154 |
| | Short-term effects of gastric bypass surgery on circulating ghrelin levels. | Q51528468 |
| | Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: a preliminary study. | Q51749947 |
| | Body mass index and all-cause mortality in a nationwide US cohort. | Q51824712 |
| | A 10-year experience with laparoscopic gastric banding for morbid obesity: high long-term complication and failure rates. | Q52012588 |
| | Ten and more years after vertical banded gastroplasty as primary operation for morbid obesity. | Q53489244 |
| | Biliopancreatic diversion in rats is associated with intestinal hypertrophy and with increased GLP-1, GLP-2 and PYY levels. | Q53511362 |
| | Paid work increases and state benefit claims decrease after bariatric surgery. | Q53566788 |
| | The core gut microbiome, energy balance and obesity | Q57012032 |
| | Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial | Q58418687 |
| P433 | issue | 1 | |
| P921 | main subject | bariatric surgery | Q357503 |
| | gastrectomy | Q827390 |
| | type 2 diabetes | Q3025883 |
| P304 | page(s) | R15-27 | |
| P577 | publication date | 2011-04-06 | |
| P1433 | published in | American Journal of Physiology - Regulatory, Integrative and Comparative Physiology | Q2201819 |
| P1476 | title | Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: understanding weight loss and improvements in type 2 diabetes after bariatric surgery | |
| P478 | volume | 301 | |